Skip to main content
. 2020 May 15;15:1071–1083. doi: 10.2147/COPD.S239841

Table 4.

Baseline Characteristics of Participants (n=174)

Control Intervention
Sex
Male, n (%) 67 (75.3) 65 (76.5)
Female, n (%) 22 (24.7) 20 (23.5)
Age, years 66.31±7.91 65.53±6.64
Education
Primary or lower, n (%) 33 (37.1) 29 (34.1)
Middle school, n (%) 36 (40.4) 34 (40.0)
High school or higher, n (%) 22 (25.9) 20 (22.5)
Smoking Status
Current smoker, n (%) 20 (22.5) 20 (23.5)
Ex-smoker, n (%) 35 (39.3) 39 (45.9)
Nonsmoker, n (%) 34 (38.2) 26 (30.6)
COPD length (years) 6.97±4.23 7.46±5.03
Stage of COPD
2 30 33
3 36 36
4 20 19
Comorbidities
None 16 15
1–2 48 48
3 or above 25 22
mMRC 2.21±0.67 2.05±0.63
CAT 23.96±3.58 24.05±3.82
6MWD 382.49±42.27 372.55±41.57
FEV1 1.15±0.47 1.29±0.44
FVC 1.82±0.56 1.89±0.57
FEV1% predicted 44.05±12.71 46.37±10.69
Self-management 125.81±16,967.54 122.92±20.34
Admission times 2 (1–2) 2 (1–2)
Admission days 16 (11–24) 16 (11–22. 5)
ED visits 0 (0–2) 1 (0–2)
Admission costs 12,897.50 (9,953.00–20,020.43) 11,585.50 (8,347.25–20,930.50)
ED-visit costs 0 (0–723.50) 524.00 (0–928.00)
Outpatient costs 700.00 (178.95–1,816.55) 673.90 (200.00–1,858.00)
Total medical costs 15,162.00 (10,297.36–22,183.10) 14,106.54 (9,475.00–23,269.05)